Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger

Fertility and Sterility

Volumn 103, Issue 4, 2015, Pages 870-873

  Fatemi, Human Mousavi ^a   Garcia Velasco, Juan ^b  

^a NOVA IVI Fertility Center   (United Arab Emirates)

^b IVI Madrid   (Spain)

Author keywords

Final oocyte maturation; GnRH agonist triggering; OHSS

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; STEROID; FERTILITY PROMOTING AGENT; GONADORELIN;

ARTICLE; CORPUS LUTEUM; EMBRYO TRANSFER; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; LUTEOLYSIS; META ANALYSIS (TOPIC); OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ADVERSE EFFECTS; AGONISTS; FEMALE; FERTILIZATION IN VITRO; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROCEDURES;

FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE;

EID: 84930805092     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2015.02.004     Document Type: Review

References (31)

1. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropinreleasing hormone (GnRH) agonist trigger and ''freeze-all'' approach in GnRH antagonist protocol. Fertil Steril 2014;101:1008-11.
2. Reis Soares S, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321-33.
3. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 2002;8: 559-77.
4. Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final oocyte maturation: Time for a change of practice? Hum Reprod Update 2011;17:510-24.
5. Cerrillo M, Pacheco A, Rodríguez S, Gomez R, Delgado F, Pellicer A, et al. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: Trying to explain the link to ovarian hyperstimulation syndrome. Fertil Steril 2011;95:2517-9.
6. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651-71.
7. Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reprod Biomed Online 2013;26:226-30.
8. Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, et al. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2013;100:742-7.
9. Haas J, Ophir L, Barzilay E, Yerushalmi GM, Yung Y, Kedem A, et al. GnRH agonist vs. hCG for triggering of ovulation-differential effects on gene expression in human granulosa cells. PLoS One 2014;9:e90359.
10. Hutchison JS, Zeleznik AJ. The rhesus monkey corpus luteum is dependent on pituitary gonadotropin secretion throughout the luteal phase of the menstrual cycle. Endocrinology 1984;115:1780-6.
11. Hutchison JS, Zeleznik AJ. The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. Endocrinology 1985;117:1043-9.
12. Dubourdieu S, Charbonnel B, Massai MR, Marraoui J, Spitz I, Bouchard P. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration. Fertil Steril 1991;56:440-5.
13. Weissman A, Lurie S, Zalel Y, Goldchmit R, Shoham Z. Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. Gynecol Endocrinol 1996;10:273-6.
14. Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online 2014;29:274-80.
15. Engmann L, di Luigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertil Steril 2008; 89:84-91.
16. Shapiro BS, Daneshmand ST, Garner FC, Aquirre M, Hudson C. Comparison of ''triggers'' using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011;95:2715-7.
17. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: A report of three cases. Reprod Biomed Online 2014;29:541-4.
18. Montanelli L, Delbaere A, di Carlo C, Nappi C, Smits G, Vassart G. Mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004; 89:1255-8.
19. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013;28:2522-8.
20. Kummer NE, Feinn RS, Griffin DW, Nulsen JC, Benadiva CA, Engmann LL. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. Hum Reprod 2013;28:152-9.
21. Asada Y, Itoi F, Honnma H, Takiguchi S, Fukunaga N, Hashiba Y, et al. Failure of GnRH agonist-striggered oocyte maturation: its cause and management. J Assist Reprod Genet 2013;30:581-5.
22. Youssef MA, van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi MohesenM, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014:CD008046.
23. YdingAndersenC,VilbourAndersenK. Improving the lutealphase afterovarian stimulation: reviewing new options. Reprod Biomed Online 2014;28:552-9.
24. Devroey P, Polyzos N, Bockell C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011;10:2593-7.
25. Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril 2012;97:527-8.
26. Fatemi HM, Popovic-Todorovic B. Implantation in assisted reproduction: A look at endometrial receptivity. Reprod Biomed Online 2013;27:530-8.
27. Farhi J, Ben-Haroush A, Andrawus N, Pinkas H, Sapir O, Fisch B. High serum oestradiol concentrations in IVF cycles increase the risk of pregnancy complications related to abnormal placentation. Reprod Biomed Online 2010;21: 331-7.
28. Henningsen AK, Pinborg A, Lidegaard Ø, Vestergaard C, Forman JL, Andersen AN. Perinatal outcome of singleton siblings born after assisted reproductive technology and spontaneous conception: Danish national sibling-cohort study. Fertil Steril 2011;95:959-63.
29. Liu HC, Kreiner D, Muasher SJ, Jones G, Jones H Jr, Rosenwaks Z. Beta-human chorionic gonadotropin as a monitor of pregnancy outcome in in vitro fertilization-embryo transfer patients. Fertil Steril 1988;50:89-94.
30. Fiddelers AA, van Montfoort AP, Dirksen CD, Dumoulin JC, Land JA, Dunselman GA, et al. Single versus double embryo transfer: costeffectiveness analysis alongside a randomized clinical trial. Hum Reprod 2006;21:2090-7.
31. Roque M, Lattes K, Serra S, Solá I, Geber S, Carreras R, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: A systematic review and meta-analysis. Fertil Steril 2013;99:156-62.